$SUNPHARMA

$SUNPHARMA Sun Pharmaceutical Industries remains one of the strongest large-cap pharmaceutical companies in India. The business is diversified across branded generics, specialty medicines, APIs, and international markets, making it relatively resilient compared with many peers. Fundamental View Positives Market leader in the Indian pharmaceutical sector with a strong domestic franchise. Healthy growth in specialty products and India business. Strong balance sheet and consistent cash generation. Continued expansion through acquisitions, including the proposed Organon acquisition, which could strengthen its global portfolio if integrated successfully. Risks US regulatory and pricing pressure remains a key concern. Integration risk from large overseas acquisitions. Proposed US tariff measures on imported generic drugs from 2028 could impact long-term sentiment for Indian pharma exporters. Technical View Primary Trend: Bullish (Long Term) The stock continues to trade above its long-term moving averages, indicating a positive structural trend. Immediate support lies near recent swing lows. A sustained breakout above the recent resistance zone can trigger fresh momentum. Traders should watch for volume confirmation before fresh entries.